Related Experiment Video
Updated: Feb 17, 2026
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
71.9K
Copeptin and insulin resistance: effect modification by age and 11 β-HSD2 activity in a population-based study
S Canivell1, M Mohaupt2, D Ackermann2
1Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, Switzerland. scanivell@gmail.com.
Journal of Endocrinological Investigation
|December 14, 2017
Summary
Age and 11β-hydroxysteroid-dehydrogenase-type 2 (11β-HSD2) activity influence the link between copeptin, a marker for arginine vasopressin (AVP), and insulin resistance. These factors, however, did not significantly affect the association with metabolic syndrome or diabetes.
Area of Science:
- Endocrinology
- Metabolic Health
- Vascular Biology
Background:
- Arginine vasopressin (AVP) is implicated in metabolic syndrome (MetS) through effects on liver glycogenolysis, insulin/glucagon secretion, and ACTH release.
- AVP also upregulates 11β-hydroxysteroid-dehydrogenase-type 2 (11β-HSD2) in mineralocorticosteroid cells.
Purpose of the Study:
- To investigate if apparent 11β-HSD2 activity modulates the association between plasma copeptin (an AVP surrogate) and insulin resistance/MetS.
- To explore the role of copeptin in metabolic health within the general adult population.
Main Methods:
- A multicentric, family-based, cross-sectional study of 1089 adults (aged 18-90 years) in Switzerland.
- Mixed multivariable regression models analyzed associations of insulin resistance (HOMA-IR)/fasting glucose and MetS/Type 2 Diabetes with copeptin.
- Results were stratified by age and estimated 11β-HSD2 activity (urinary cortisol/cortisone ratio).
Main Results:
- Plasma copeptin levels were higher in men than women.
- HOMA-IR showed a positive association with copeptin when 11β-HSD2 activity or age was high, but not when they were low.
- Type 2 diabetes was positively associated with copeptin, but MetS was not.
Conclusions:
- Age and apparent 11β-HSD2 activity appear to modulate the relationship between copeptin and insulin resistance at a population level.
- These factors did not significantly influence the association between copeptin and MetS or diabetes.
- Further research is warranted to confirm these findings and elucidate underlying mechanisms.
Related Concept Videos
01:16Insulin: Dosing Regimen and Adverse Effects
857
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
857
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
696
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
696
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
232
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
232
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
268
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
268
01:22Diabetes Mellitus: Type 2 and Gestational
5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
242
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
242